Οικονομική αξιολόγηση ενός βιολογικού ανοσοτροποποιητικού αντιρρευματικού φαρμάκου για την αντιμετώπιση της Νεανικής Ιδιοπαθούς Αρθρίτιδας
Economic evaluation of a biological disease-modifying antirheumatic drug for treating Juvenile Idiopathic Arthritis
View/
Subject
Ιατρική περίθαλψη, Κόστος τηςKeywords
Υγεία ; Ρευματικές παθήσεις ; ΦάρμακαAbstract
Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease that occurs in
children aged below 16 years and persists for more than 6 weeks and can become a cause
of functional impairment.
The disease is of unknown etiology, characterized by joint pain, swelling and
movement limitation, symptoms caused by inflammation of the synovial membrane of
the affected joint. NIA is divided into 7 subtypes based on the clinical features of the
disease lasting for more than six months – oligoarthritis, polyarthritis RF+ or RF-,
psoriatic arthritis, systemic arthritis, arthritis related to enthesitis and undifferentiated
arthritis.
The treatment of children with NIA was based on non-steroidal anti-inflammatory
drugs, with the addition of corticosteroids. Later, methotrexate, the most common
conventional non-biological antirheumatic drug, was used, while the current preferred
treatment makes use of the biological drug-modifying drugs.
The purpose of this health technology assessment is to evaluate the cost-effectiveness
of NIA treated with adalimumab, a biological modifying antirheumatic drug (Humira®,
AbbVie) in combination with methotrexate, compared to conventional methotrexate
therapy.
Patients receiving biologic treatment with adalimumab experienced fewer disease
flares as well as fewer adverse events than those treated only with methotrexate. However,
there is limited evidence for the clinical effectiveness of the biological treatment in
specific subtypes of the disease.
Based on the developed independent model for the purposes of the current assessment,
the incremental cost-effectiveness ratio (ICERs) for the treatment with adalimumab
compared to the conventional treatment with methotrexate is estimated at EUR 25,659
per QALY gained, using the drug price list acquisition costs.
Model results are more sensitive to changes in HRQoL utility values. Changes in
clinical effectiveness parameters, such as discontinuation of treatment and disease flares,
had little effect on the model's results.
Postgraduate Studies Programme
Οικονομικά και Διοίκηση της ΥγείαςDepartment
Σχολή Οικονομικών, Επιχειρηματικών και Διεθνών Σπουδών. Τμήμα Οικονομικής ΕπιστήμηςNumber of pages
100Language
GreekCollections
Except where otherwise noted, this item's license is described as
Attribution-NonCommercial-NoDerivatives 4.0 Διεθνές
Attribution-NonCommercial-NoDerivatives 4.0 Διεθνές